Evaluation of the effect of N acetylcysteine on the prevention of peripheral neuropathy induced by taxanes : a randomized double-blind placebo- controlled trial

Mazandaran University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2023年5月1日

适应症

试验速览

暂无简介。

•AC-T regimen recipient
•People over 18 years old
•For normal bone marrow function (ANC>1500/mm3 and Plt>100000//mm3)
•Having normal liver function (bili<1.5 mg/dl - liver enzymes level less than three times the maximum normal range) and normal kidney function (cr<1.5 mg/dl)
•Normal baseline ECG

•Patients with previous history of neurological diseases such as hereditary and acquired neuropathies
•Patients with neuropathic pain due to conditions such as postherpetic neuralgia, uncontrolled diabetes with neuropathy, trigeminal neuralgia, spinal cord injury or other neurological diseases, known vitamin B12 deficiency, amyloidosis, neuromuscular diseases and connective tissue diseases.
•Creatinine clearance less than 30 ml/min
•Severe liver failure (liver enzymes more than three times the normal limit)
•History of allergy and sensitivity to N-acetylcysteine
•Uncontrolled diabetes
•Alcoholic patients
•chronic use of vitamin B1 and supplements containing magnesium
•Taking antiepileptic drugs
•Use of opioids
•Pregnant or lactating women
•Lack of consent to participate in the study

发起方